Press Releases
Hyperion Therapeutics to Present at UBS 2009 Global Life Sciences Conference
SOUTH SAN FRANCISCO, California - September 18, 2009Hyperion Therapeutics, Inc. today announced that Donald Santel, Chief Executive Officer, will present at the UBS 2009 Global Life Sciences Conference on Wednesday September 23, 2009 at 4:30 pm ET. The conference will be held at the Grand Hyatt New York in New York City.
About Hyperion Therapeutics
Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs and underserved patient populations in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 (glycerol phenylbutyrate) in August 2007. Under the terms of the agreement, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com.
Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs and underserved patient populations in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 (glycerol phenylbutyrate) in August 2007. Under the terms of the agreement, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com.
Press contact:
Christine Nash
Hyperion Therapeutics, Inc.
650-745-7844
Christine Nash
Hyperion Therapeutics, Inc.
650-745-7844